Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Type 1 Diabetes
Interventions: Time Limited Eating; Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 25 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Determine the Effects of Nitrosigine and Citrulline-malate on Flow-mediated Dilation Among Young Adults
Interventions: inositol-stabilized arginine silicate; Dietary Supplement
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 18 Years to 29 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Type 2 Diabetes
Interventions: HM11260C, liraglutide, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: CA, California

Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions: Minnelide™Capsules; Drug
Lead sponsor: Minneamrita Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more

Conditions: Substance Use Disorders, HIV
Interventions: PrEP navigation + text messaging, Standard of Care, Contingency Management; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Moderate to Severe Opioid-use Disorder
Interventions: Transmucosal Buprenorphine, Extended-release Buprenorphine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 785 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 28
States / cities: Garden Grove, California • Panorama City, California • San Diego, California + 21 more

Conditions: Axial Spondyloarthritis
Interventions: Dietary recommendations; Other
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Healthy Adults
Interventions: EC5026 oral tablet, Placebo oral tablet; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metastatic Urothelial Carcinoma
Interventions: pembrolizumab, ACP-196 in combination with pembrolizumab; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Durham, North Carolina + 4 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine, Venetoclax, FHD-286; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Staphylococcus Aureus, Methicillin-resistant Staphylococcus Aureus, Nosocomial Disease
Interventions: Not listed
Lead sponsor: Landon Pediatric Foundation; Other
Eligibility: 1 Year to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Ventura, California

Conditions: Pain, Acute, Pain, Procedural
Interventions: Speed of tenaculum application; Procedure
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog; Device · Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diagnostic Self Evaluation
Interventions: Cytologic techniques used for rapid on site interpretation; Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hepatic Impairment
Interventions: Enasidenib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: Type 2 Diabetes Mellitus
Interventions: Raspberries; Other
Lead sponsor: Oklahoma State University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Conditions: Healthy
Interventions: Loperamide HCl 2 mg and simethicone 125 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Acupuncture, Low Back Pain
Interventions: NSAIDS, Battlefield Acupuncture, GV26 with manual tonification; Drug · Device
Lead sponsor: David Moss; Federal
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Chronic Kidney Diseases
Interventions: Bardoxolone methyl oral capsule, Placebo oral capsule; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 12
States / cities: La Mesa, California • Arvada, Colorado • Denver, Colorado + 9 more

Conditions: Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm
Interventions: Biopsy, Medical Chart Review, Thoracoscopy; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Nashville, Tennessee • Houston, Texas

Conditions: Migraine Disorders
Interventions: Combination Product (sumatriptan succinate / naproxen sodium), Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 26
States / cities: Fresno, California • Newport Beach, California • Santa Monica, California + 23 more

Conditions: Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: solifenacin succinate suspension, solifenacin succinate tablet; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Spinal Cord Injuries, Endothelial Dysfunction, Testosterone Deficiency
Interventions: Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling; Diagnostic Test
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Diabetes Mellitus
Interventions: genetic testing for type 2 diabetes, Conventional risk counseling, eye disease counseling; Genetic · Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 65 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Time Limited Eating in Type 1 Diabetes

Evaluation of Sports Supplements on Blood Flow

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

ASK-PrEP (Assistance Services Knowledge-PrEP)

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Microbiome and Axial Spondyloarthritis

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Volatile Organic Compounds in Staphylococcus Aureus Patients

RCT of Pain Perception With Fast and Slow Tenaculum Application

Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)

Diagnostic Efficiency of Touch Imprints Versus Smears

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Raspberries and Postprandial Metabolism

Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions

Accessible Acupuncture for the Warrior With Acute Low Back Pain

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury

Genetic Testing for Type 2 Diabetes